Edgestream Partners L.P. bought a new stake in Bristol Myers Squibb Company (NYSE:BMY – Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 193,465 shares of the biopharmaceutical company’s stock, valued at approximately $12,072,000.
Several other institutional investors and hedge funds have also modified their holdings of BMY. Pinion Investment Advisors LLC raised its stake in Bristol Myers Squibb by 3.8% in the 3rd quarter. Pinion Investment Advisors LLC now owns 4,316 shares of the biopharmaceutical company’s stock worth $269,000 after purchasing an additional 158 shares in the last quarter. Altura Wealth Advisors Inc. grew its position in shares of Bristol Myers Squibb by 1.2% during the 3rd quarter. Altura Wealth Advisors Inc. now owns 13,717 shares of the biopharmaceutical company’s stock worth $856,000 after purchasing an additional 161 shares in the last quarter. Capital City Trust Co. FL grew its position in shares of Bristol Myers Squibb by 0.7% during the 3rd quarter. Capital City Trust Co. FL now owns 23,321 shares of the biopharmaceutical company’s stock worth $1,455,000 after purchasing an additional 167 shares in the last quarter. Eagle Bay Advisors LLC grew its position in shares of Bristol Myers Squibb by 2.6% during the 3rd quarter. Eagle Bay Advisors LLC now owns 6,536 shares of the biopharmaceutical company’s stock worth $408,000 after purchasing an additional 168 shares in the last quarter. Finally, Blue Bell Private Wealth Management LLC increased its holdings in shares of Bristol Myers Squibb by 21.1% during the third quarter. Blue Bell Private Wealth Management LLC now owns 969 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 169 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.
Bristol Myers Squibb Trading Down 0.7%
Shares of Bristol Myers Squibb stock opened at $62.96 on Tuesday. The company has a market capitalization of $128.69 billion, a price-to-earnings ratio of 13.96, a PEG ratio of 0.32 and a beta of 0.20. The company has a quick ratio of 1.44, a current ratio of 1.59 and a debt-to-equity ratio of 1.79. Bristol Myers Squibb Company has a 12-month low of $45.26 and a 12-month high of $68.64. The firm’s 50-day moving average price is $61.82 and its two-hundred day moving average price is $60.35.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.10 by $0.25. The firm had revenue of $13.07 billion for the quarter, compared to analyst estimates of $12.72 billion. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The business’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same period last year, the firm earned $1.63 EPS. On average, analysts forecast that Bristol Myers Squibb Company will post 6.46 earnings per share for the current fiscal year.
Bristol Myers Squibb Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.0%. The ex-dividend date of this dividend was Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.88%.
Insider Buying and Selling
In other Bristol Myers Squibb news, Director Julia A. Haller sold 3,800 shares of the company’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total transaction of $240,578.00. Following the completion of the sale, the director directly owned 30,279 shares in the company, valued at $1,916,963.49. This represents a 11.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.05% of the company’s stock.
Analyst Upgrades and Downgrades
BMY has been the subject of a number of analyst reports. TD Cowen started coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a “buy” rating for the company. Guggenheim reissued a “buy” rating and set a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Morgan Stanley lowered their price objective on Bristol Myers Squibb from $41.00 to $40.00 and set an “underweight” rating on the stock in a research note on Friday, October 30th. Cantor Fitzgerald dropped their price objective on Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating for the company in a report on Thursday, October 8th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $76.00 price objective on shares of Bristol Myers Squibb in a report on Monday, October 12th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $65.46.
View Our Latest Analysis on Bristol Myers Squibb
Bristol Myers Squibb Profile
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.
Featured Stories
- Five stocks we like better than Bristol Myers Squibb
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
